NCT00584714终止不适用
Long-Term Follow-Up of Selected Patients Enrolled in Phase 3 Clinical Trial 127-014 Using PB127 Ultrasound Imaging Agent
Point Biomedical39 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2007年10月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 300
- 试验地点
- 39
- 主要终点
- To collect longer-term follow-up clinical information on selected patients enrolled in Protocol 127-014
研究概览
简要总结
The purpose of this study is to collect longer term follow-up information concerning health and survival on selected patients who received PB127 for injectable suspension in the pivotal trial (127-014).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients enrolled in Protocol 127-014 who
- •Were enrolled in Stratum 1
- •Did not undergo angiography during study evaluation
- •Did not have a clinical oucome during the initial 6 month follow-up period as described in Protocol 127-014.
排除标准
- 未提供
结局指标
主要结局
To collect longer-term follow-up clinical information on selected patients enrolled in Protocol 127-014
时间窗: 1 year
次要结局
未报告次要终点
研究者
研究点 (39)
Loading locations...
相似试验
招募中
不适用
Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical StudyParticipants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical StudyNCT05822427Imugene Limited75
Enrolling By Invitation
不适用
A Long Term Follow-Up Study for Subjects Who Have Received Q-CellsTransverse MyelitisNCT06163508University of Texas Southwestern Medical Center9
已完成
不适用
Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550Arthritis, RheumatoidNCT00414661Pfizer162
已完成
不适用
Long-term Data Collection for Subjects in MDX-010 StudiesMetastatic MelanomaNCT00928031Bristol-Myers Squibb160
已完成
不适用
A Follow up Study of Patients Treated With Imlifidase Prior to Kidney TransplantationKidney Transplant Failure and RejectionNCT03611621Hansa Biopharma AB31